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Oral lichen planus (OLP) is a relatively common skin and oral disease that manifests as a mucous reaction
to a variety of etiologic factors, including autoimmune disease, drug reaction, diabetes mellitus (DM),
hypertension, hepatitis C virus (HCV), urolithiasis, psychogenic factors, and bacterial infection. The
purpose of this study was to investigate the relationship between HCV infection and OLP as there is a
high prevalence of HCV infection in Taiwan. A total of 1,075 subjects aged at least 15 years participated
in the study. The total prevalence of OLP was 3% (32/1,075). OLP was significantly associated with DM
(odds ratio, OR, 3.09) and HCV (OR, 2.05). Atrophic-erosive OLP (13/32) and reticular OLP (21/32) were
significantly associated with HCV and DM, respectively. Logistic regression analysis showed that elevation
of alanine aminotransferase (ALT) significantly increased the risk of atrophic-erosive OLP. We concluded
that OLP is significantly associated with HCV and DM in southern Taiwan, particularly in HCV patients
with elevated serum ALT levels and atrophic-erosive OLP.
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Oral lichen planus (OLP) is a common benign disease in
many countries [1]. The overall prevalence of OLP varies in
different studies from 0.02% to 1.9% [2,3]. OLP represents a
mucous reaction seen in a variety of conditions such as
diabetes mellitus (DM), hypertension, rheumatic-collagen
disease, urolithiasis, chronic liver disease, exposure to
idiosyncratic drugs, chemicals or dental restorations, and
betel quid chewing [1,4]. In 1978, the controversial relation-
ship between lichen planus and chronic liver disease was
first reported [5]. In 1988, Cottoni et al reported that 28 of 62
lichen planus cases were associated with other diseases,
including 16 cases of chronic liver disease and five cases of
DM [6]. In 1994, Jubert et al described six cases of lichen
planus associated with chronic active hepatitis and actively
replicating hepatitis C virus (HCV) [7]. Recently, van der
Meij and van der Waal stated that the 18 published studies
on HCV infection and OLP suggest that HCV is the main
cause of liver disease in patients with OLP and could be
involved in the development of OLP [8]. Thus, geographic
differences in the prevalence of OLP associated with HCV
infection might simply reflect overall differences in HCV
epidemiology.
A community survey revealed a 2.5% prevalence of
HCV infection among 1,500 subjects in a northern county in
Taiwan [9]. In another study conducted in eastern Taiwan,
the prevalence was 3.6% in some villages and 20% to 30% in
others [10]. The significant difference in the prevalence of
HCV infection among the villages was suspected to be
associated with OLP. The association between HCV and
OLP has not been thoroughly investigated in Taiwan. The
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purpose of this study was to identify the association between
HCV and OLP in southern Taiwan.
MATERIALS AND METHODS
A community-based sample was chosen for this study.
Using high hepatoma mortality and high average alanine
aminotransferase (ALT) levels as the criteria for high HCV
prevalence, two villages with high prevalence and three
villages with low prevalence were selected using the Tai-
wan Cancer Mortality Map and ALT data from local health
bureaus in Tainan and Kaohsiung prefectures in southern
Taiwan. Between September 1998 and April 1999, partici-
pants aged at least 15 years were clinically examined.
Oral examination and diagnosis of oral mucous
lesions
The diagnostic criteria for OLP were based on the
recommendation of the World Health Organization in 1980
[11] and the Scully classification [1]. Reticular OLP was
defined by the presence of slender white lines (Wickham’s
striae) radiating from the plaque, atrophic OLP by a diffuse
red area and whitish Wickham’s striae of the oral mucosa,
and erosive OLP by lesions of atrophic type with ulcers.
Participants were divided into two groups according to the
clinical type of lesion observed: reticular OLP (group 1) and
atrophic-erosive OLP (group 2).
Serum sample collection and analysis
Blood (10 mL) was drawn from each subject and serum
samples were stored at –20°C. Anti-HCV antibodies to
HCV-encoded antigens (c100-3, c33, c22) were assayed
using a third-generation HCV enzyme immunosorbent assay
(ELISA) system according to the manufacturer’s instructions
(Abbott 3.0 Anti-HCV EIA; Abbott Laboratories, Abbott
Park, IL, USA). Samples with optical densities above the
cutoff value were considered positive. Reactive samples
were retested and were considered positive if both tests
were reactive. Serum ALT and aspartate aminotransferase
(AST) levels were determined using a kinetic assay with
commercial reagents (dry chemistry multi-film; Eastman
Kodak Company, Rochester, NY, USA) in a Kodak Ektachem
700XR Analyzer C Series (Eastman Kodak Company). ALT
levels of more than 55 U/L and AST levels of more than
45 U/L were considered abnormal.
Interview
Trained research assistants or public health nurses inter-
viewed study subjects using a structured questionnaire.
The questionnaire gathered data on age, gender, educa-
tion years, and medical history. Subjects were considered
to have drug or food allergies, DM, kidney/urinary tract
stone, or hypertension if this had been diagnosed by phy-
sicians before the study or if they were currently taking
medication for the disease.
Statistical analysis
Oral examination results and information from the
questionnaires were analyzed using the SAS statistical
software package, version 8.0 (SAS Institute Inc, Cary, NC,
USA). Associations between OLP and each variable in the
questionnaire were tested using the Chi-squared or Fisher’s
exact test. Relationships between two categorical variables
were tested using the Chi-squared test. However, for tables
with more than 20% of expected cell sizes less than 5,
Fisher’s exact test was used. Logistic regression analysis
was used to investigate the associations of HCV, serum
ALT and serum AST with OLP. Results were considered
statistically significant if the p value was less than 0.05.
RESULTS
A total of 1,075 subjects participated in the study. The
average age was 49.81 ±  17.34 years (mean ±  standard
deviation). The total prevalence of OLP was 3% (32/1,075).
The associations of OLP with gender, age, educational
level, medical history, and serum ALT and AST levels are
shown in Table 1. The prevalence among men (3.61%) was
higher than among women (2.37%); the highest prevalence
was found in patients aged at least 65 years (5.00%), but this
was not statistically significant. The occurrence of OLP was
significantly associated with DM (OR, 3.09; p = 0.019) and
HCV (OR, 2.05; p = 0.044).
OLP was divided into only two subtypes, reticular and
atrophic-erosive, because the appearance of erosive OLP is
similar to that of atrophic OLP but it is very rare. Of the 32
patients with OLP, 21 (65.6%) had reticular OLP and 13
(40.6%) had atrophic-erosive OLP; two patients had mixed
type in their oral cavity. The associations of OLP subtype
with DM, HCV and ALT and AST levels are shown in Tables
2 and 3. Reticular OLP was significantly associated with
DM (OR, 3.90; p = 0.032) and atrophic-erosive OLP was
significantly associated with HCV (OR, 3.05; p = 0.037) and
a serum ALT of more than 55 U/L (OR, 3.65; p = 0.014).
In the serum analysis, we found that OLP was not associated
with AST (OR, 1.01; p = 0.989) or ALT levels (OR, 1.94; p = 0.084)
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(Table 1), but atrophic-erosive OLP was significantly associated
with ALT level (OR, 3.65; p = 0.014) (Table 3). Logistic regression
analysis for participants with atrophic-erosive OLP with HCV
infection showed that ALT had a significant synergistic effect
(Table 4). The prevalence of atrophic-erosive OLP among
subjects with HCV infection and elevated ALT was 20.1-fold
higher (95% confidence interval, 95% CI, 4.48–89.85) than in
healthy subjects. The prevalence among participants who only
had HCV infection without elevated ALT was 1.6-fold higher
(95% CI, 0.31–8.49) than in healthy participants.
Table 1. Association of oral lichen planus (OLP) prevalence with demographic data and medical history
OLP
Yes, n (%) No, n (%) OR p* 95% CI
Gender
Male 19 (3.61) 507 (96.39) 0.65 0.230 0.32, 1.32
Female 13 (2.37) 536 (97.63) 1.00
Age (yr)
15–24 2 (1.74) 113 (98.26) 1.00
25–34 4 (3.45) 112 (96.55) 2.02 0.683† 0.36, 11.24
35–44 4 (2.12) 185 (97.88) 1.22 1.000† 0.22, 6.78
45–54 0 (0.00) 183 (100.00) 0.12 0.148† 0.01, 2.60
55–64 10 (4.31) 222 (95.69) 2.55 0.350† 0.55, 11.81
≥ 65 12 (5.00) 228 (95.00) 2.97 0.242† 0.65, 13.51
Education (yr)
≤ 9 29 (2.91) 967 (97.09) 0.76 0.506† 0.23, 2.55
> 9 3 (3.80) 76 (96.20) 1.00
Allergy
Yes 6 (4.44) 129 (95.56) 1.64 0.283 0.67, 4.05
No 26 (2.77) 914 (97.23) 1.00
Diabetes mellitus
Yes 5 (7.81) 59 (92.19) 3.09 0.019 1.15, 8.31
No 27 (2.67) 984 (97.33) 1.00
Hypertension
Yes 5 (3.13) 155 (96.88) 1.06 0.905 0.40, 2.80
No 27 (2.95) 888 (97.05) 1.00
Stone
Yes 1 (1.72) 57 (98.28) 0.56 1.000† 0.08, 4.16
No 31 (3.05) 986 (96.95) 1.00
Hepatitis C virus
Yes 14 (4.65) 287 (95.35) 2.05 0.044 1.01, 4.18
No 18 (2.33) 756 (97.67) 1.00
Aspartate aminotransferase
> 45 U/L 5 (2.99) 162 (97.01) 1.01 0.989 0.38, 2.66
≤ 45 U/L 27 (2.97) 881 (97.03) 1.00
Alanine aminotransferase
> 55 U/L 10 (4.81) 198 (95.19) 1.94 0.084 0.92, 4.11
≤ 55 U/L 22 (2.54) 845 (97.46) 1.00
*χ2 or †Fisher’s exact test. OR = odds ratio; 95% CI = 95% confidence interval.
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DISCUSSION
Demographic analysis in this study showed that OLP is a
disease of adulthood occurring at ages ranging from 30 to
70 years and afflicting both sexes, although some surveys
have found that 60% to 65% of patients are female [1]. We
also found that there was a greater prevalence of OLP in
males older than 65 years with a higher education level, but
the difference was not significant.
The relationship between DM and OLP was suggested
by Grinspan et al [12], and since then, many investigators
have studied the problem. The prevalence of OLP in patients
with DM varies from 0% to 5.7% (Table 5) [12–21]. A match-
pair study by Van Dis and Parks showed no association
Table 2. Relationship between prevalence of reticular oral lichen planus (OLP) and diabetes mellitus, hepatitis C virus, and
levels of aspartate aminotransferase and alanine aminotransferase
Reticular OLP
Yes, n (%) No, n (%) OR p* 95% CI
Diabetes mellitus
Yes 4 (6.25) 60 (93.75) 3.90 0.032† 1.38, 11.05
No 17 (1.68) 994 (98.32) 1.00
Hepatitis C virus
Yes 8 (2.66) 293 (97.34) 1.60 0.298 0.66, 3.87
No 13 (1.68) 761 (98.32) 1.00
Aspartate aminotransferase
> 45 U/L 3 (1.80) 164 (98.20) 0.90 1.000† 0.26, 3.11
≤ 45 U/L 18 (1.98) 890 (98.02) 1.00
Alanine aminotransferase
> 55 U/L 5 (2.40) 203 (97.60) 1.31 0.601 0.48, 3.61
≤ 55 U/L 16 (1.85) 851 (98.15) 1.00
*χ2 or †Fisher’s exact test. OR = odds ratio; 95% CI = 95% confidence interval.
Table 3. Association between the prevalence of atrophic-erosive oral lichen planus (OLP) and diabetes mellitus, hepatitis C
virus, and levels of aspartate aminotransferase and alanine aminotransferase
Atrophic-erosive OLP
Yes, n (%) No, n (%) OR p* 95% CI
Diabetes mellitus
Yes 2 (3.13) 62 (96.88) 2.93 0.179† 0.68, 12.62
No 11 (1.09) 1,000 (98.91) 1.00
Hepatitis C virus
Yes 7 (2.33) 294 (97.67) 3.05 0.037 1.07, 8.68
No 6 (0.78) 768 (99.22) 1.00
Aspartate aminotransferase
> 45 U/L 2 (1.20) 165 (98.80) 0.99 1.000† 0.22, 4.50
≤ 45 U/L 11 (1.21) 897 (98.80) 1.00
Alanine aminotransferase
> 55 U/L 6 (2.88) 202 (97.12) 3.65 0.014 1.30, 10.23
≤ 55 U/L 7 (0.81) 860 (99.19) 1.00
*χ2 or †Fisher’s exact test. OR = odds ratio; 95% CI = 95% confidence interval.
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Table 4. Logistic regression analysis for oral lichen planus (OLP) with hepatitis C virus (HCV) and levels of aspartate
aminotransferase (AST) and alanine aminotransferase (ALT)
Variable Parameter estimate SE Wald χ2    p OR Confidence limit OLP
Lower Upper n/Total %
Total
Intercept –3.78 0.26 209.85 0.0001
HCV+ALT+AST 0.34 0.64 0.28 0.5986 1.40 0.40 4.94 3/97 3.09
HCV+ALT 2.22 0.61 13.35 0.0003 9.25 2.80 30.51 4/23 17.39
ALT+AST 0.76 0.77 0.98 0.3221 2.14 0.47 9.69 2/43 4.65
HCV 0.66 0.47 2.00 0.1571 1.93 0.78 4.82 7/166 4.22
ALT 0.00 1.04 0.00 0.9988 1.00 0.13 7.73 1/45 2.22
Reticular OLP
Intercept –4.10 0.30 181.79 0.0001
HCV+ALT+AST –0.47 1.05 0.20 0.6576 0.63 0.08 4.92 1/97 1.03
HCV+ALT 1.75 0.80 4.77 0.0289 5.74 1.20 27.54 2/23 8.70
ALT+AST 1.08 0.79 1.89 0.1697 2.94 0.63 13.71 2/43 4.65
HCV 0.63 0.55 1.32 0.2513 1.87 0.64 5.46 5/166 3.01
Atrophic-erosive OLP
Intercept –4.90 0.45 118.98 0.0001
HCV+ALT+AST 1.04 0.84 1.51 0.2197 2.82 0.54 14.72 2/97 2.06
HCV+ALT 3.00 0.76 15.38 0.0001 20.07 4.48 89.85 3/23 13.04
HCV 0.49 0.84 0.34 0.5605 1.63 0.31 8.49 2/166 1.20
ALT 1.11 1.11 1.01 0.3148 3.04 0.35 26.60 1/45 2.22
SE = standard error; OR = odds ratio.
Table 5. Studies of oral lichen planus (OLP) prevalence in patients with diabetes mellitus (DM)
Study DM, n OLP, n %
Grinspan et al 1965 [12] 70 4 5.71
Martinez Pena 1982 [13] 100 0 0
Lozada-Nur et al 1985 [14] 119 2 1.68
Borghelli et al 1987 [15] 240 1 0.42
Borghelli et al 1988 [16] 584 1 0.17
Albrecht et al 1992 [17] 1,600 (621) 17 (0) 1 (0)
Borghelli et al 1993 [18] 729 (676) 4 (6) 0.55 (0.7)
Van Dis and Parks 1995 [19] 161 (161) 11 (8) 4 (3)
Petrou-Amerikanou et al 1998 [20] 492 (274) 18 (5) 4.2 (1.82)
Guggenheimer et al 2000 [21] 405 (268) 2 (2) 0.5 (0.7)
Chung et al 2004 [present study] 64 (1,011) 5 (27) 7.8 (2.67)
Numbers in parentheses = control group.
between DM and OLP [19]. The prevalence of DM in patients
with OLP varies from 1.6% to 38.9% [13,14,22–29] (Table 6).
The variation in prevalence is due to differences in criteria
for DM. Bagan et al showed that atrophic-erosive lesions
are common in patients with OLP associated with DM [29].
The present study showed that the prevalence of OLP
among participants with DM was 7.8%, 3.09-fold higher
than in normal subjects. Reticular OLP was associated with
DM (OR, 3.90; 95% CI, 1.38–11.05). This result is not compa-
tible with that of Bagan et al’s study and requires more par-
ticipants for further analysis.
The relationship between OLP and HCV infection
remains controversial. Table 7 summarizes the 11 studies of
the relationship between OLP and HCV infection with
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control groups published between 1994 and 1999 [30–40].
Significant associations were found in southern European
countries [33,34,37,38], the USA [31,40], Germany [36], and
Japan [32]. On the other hand, no significant association
was found in the UK [39], France [30,35], or the Netherlands
[8]. Geographic differences in the association of OLP with
HCV infection might simply reflect overall differences in
HCV prevalence. These were mostly hospital-based studies.
Nine showed that OLP was significant in HCV infection.
The present community-based study found a significant
association between OLP and HCV infection in southern
Taiwan. The prevalence of atrophic-erosive OLP among
participants with HCV infection was three-fold higher than
in healthy people. This result is compatible with the Sanchez-
Perez et al study [34]. We also noted the synergistic effect of
ALT, but not AST, elevation on the prevalence of atrophic-
erosive OLP. Among participants with HCV infection and
elevated ALT, the prevalence of atrophic-erosive OLP was
20-fold higher than in healthy people. On the other hand,
among participants with HCV infection but no elevation of
ALT, the prevalence was 1.63-fold. This suggests that the
host effect is a more important factor than the viral effect in
the relationship between OLP and HCV.
OLP represents a mucous reaction seen in a variety of
conditions such as DM, hypertension, rheumatic-collagen
disease, urolithiasis, chronic liver disease, and exposure to
idiosyncratic drugs and chemicals. This study showed that
OLP is associated with HCV infection and DM in southern
Taiwan.
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